Mga Batayang Estadistika
| LEI | 549300JLJLICQGQFXF87 |
| CIK | 861838 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Idera Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0167 Expires: July 31, 2024 Estimated average burden hours per response 1.50 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Aceragen, Inc. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-31918 Aceragen, Inc. Nasdaq Capital Market (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 505 Eagleview Bl |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
Exhibit 10.1 EXECUTIVE SEPARATION AGREEMENT This Executive Separation Agreement (this “Agreement”), is entered into as of August 15, 2023 (the “Execution Date”), by and between John Taylor (“you”) and Aceragen, Inc., a Delaware corporation (together with its wholly owned subsidiaries and affiliates, the “Company”). BACKGROUND WHEREAS, you currently serve as Chief Executive Officer of the Company; |
|
| August 16, 2023 |
Exhibit 10.2 GENERAL ASSIGNMENT FOR THE BENEFIT OF CREDITORS THIS GENERAL ASSIGNMENT FOR THE BENEFIT OF CREDITORS (the “General Assignment”) is made this 16th day of August, 2023 (the “Effective Date”), by and between Aceragen, Inc., a Delaware corporation located at 505 Eagleview Boulevard, Exton, PA 19341, Federal Tax Identification Number 04-3072298, hereinafter referred to as “Assignor” and AC |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 3, 2023 |
US00445F1093 / ACERAGEN INC / Pillar Pharmaceuticals 6, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| August 3, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) EX-99.1 2 d505085dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 Aceragen, Inc. |
|
| July 21, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| July 17, 2023 |
US00445F1093 / ACERAGEN INC / Pillar Pharmaceuticals 6, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| July 17, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The under |
|
| July 11, 2023 |
Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[****]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. BRIDGE FUNDING AGREEMENT This Bridge Funding Agreement (this “Agreement”) is entered into as of July 11, 2023 (the “Effective |
|
| July 11, 2023 |
Exhibit 10.3 SECURITY AGREEMENT THIS SECURITY AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time, this “Security Agreement”) is entered into as of July 11, 2023, by Aceragen, Inc., a Delaware corporation (“Aceragen” and together with any additional obligors joined as parties hereto, collectively, “Grantor”), and NovaQuest Co-Investment Fund |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Aceragen, Inc. |
|
| July 11, 2023 |
Exhibit 10.1 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of July 10, 2023, by and among Aceragen, Inc., a Delaware corporation (together with its subsidiaries, “Aceragen”) and [●], a stockholder of Aceragen listed on Schedule A hereto (the “Securityholder”). RECITALS: A. The Securityholder owns beneficially and of record the shares of capital st |
|
| July 11, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Aceragen, Inc. |
|
| July 11, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to . Commission File Number: 001-31918 Acer |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 Aceragen, Inc. |
|
| May 30, 2023 |
Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing Exhibit 99.1 Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing DURHAM, NC and EXTON, PA, May 30, 2023 — Aceragen, Inc. (the “Company”) (Nasdaq: ACGN), announced today that on May 24, 2023, the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ende |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-31918 CUSIP Number: 00445F109 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: March 31, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tran |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 Aceragen, Inc. |
|
| April 13, 2023 |
Exhibit 10.39 AMENDMENT NO. 1 TO EXECUTIVE TRANSITION AND SEPARATION AGREEMENT This Amendment No. 1 to Executive Transition and Separation Agreement (this “Agreement”), is entered into as of the date set forth on the signature page below (the “Execution Date”), by and between Daniel Soland (“You”) and Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.), a Delaware corporation (together |
|
| April 13, 2023 |
Exhibit 4.23 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Aceragen, Inc.’s (“Aceragen,” “we,” “us,” and “our”) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description is a summary a |
|
| April 13, 2023 |
Exhibit 10.26 ACERAGEN, INC. NONQUALIFIED STOCK OPTION GRANT AGREEMENT GRANTED PURSUANT TO THE 2022 EQUITY INCENTIVE PLAN FOR DIRECTORS OF THE COMPANY This NONQUALIFIED STOCK OPTION GRANT AGREEMENT (the “Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.) (the “Company”) to [●] (the “Participant”). RECITALS The Idera Ph |
|
| April 13, 2023 |
Form of Nonstatutory Stock Option Agreement granted under the 2022 Stock Incentive Plan Exhibit 10.25 ACERAGEN, INC. NONQUALIFIED STOCK OPTION GRANT AGREEMENT GRANTED PURSUANT TO THE 2022 EQUITY INCENTIVE PLAN This NONQUALIFIED STOCK OPTION GRANT AGREEMENT (the “Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.) (the “Company”) to [●] (the “Participant”). RECITALS The Idera Pharmaceuticals, Inc. 2022 Equi |
|
| April 13, 2023 |
Exhibit 4.22 THIS AMENDED AND RESTATED WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQ |
|
| April 13, 2023 |
Form of Incentive Stock Option Agreement granted under the 2022 Stock Incentive Plan Exhibit 10.24 ACERAGEN, INC. INCENTIVE STOCK OPTION GRANT AGREEMENT GRANTED PURSUANT TO THE 2022 EQUITY INCENTIVE PLAN This INCENTIVE STOCK OPTION GRANT AGREEMENT (the “Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.) (the “Company”) to [●] (the “Participant”). RECITALS The Idera Pharmaceuticals, Inc. 2022 Equity Inc |
|
| April 13, 2023 |
Exhibit 10.30 AMENDMENT NO. 1 TO EXECUTIVE TRANSITION AND SEPARATION AGREEMENT This Amendment No. 1 to Executive Transition and Separation Agreement (this “Agreement”), is entered into as of the date set forth on the signature page below (the “Execution Date”), by and between Vincent Milano (“You”) and Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.), a Delaware corporation (together |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-31918 Aceragen, Inc. (Exact name of Registrant as |
|
| April 10, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The under |
|
| April 10, 2023 |
US00445F1093 / ACERAGEN INC / Pillar Pharmaceuticals 6, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ⌧ Form 10-K ◻ Form 20-F ◻ Form 11-K ◻ Form 10-Q ◻ Form 10-D ◻ Form N-SAR ◻ Form N-CSR For Period Ended: December 31, 2022 ◻ Transition Report on Form 10-K ◻ Transition Report on Form 20-F ◻ Transition Report on Form 11-K ◻ Transition Report on Form 10-Q ◻ Transition Report o |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2023 Aceragen, Inc. |
|
| March 28, 2023 |
US00445F1093 / ACERAGEN INC / Chopra Atul - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Aceragen, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00445F109 (CUSIP Number) Christopher J. Hubbert 1375 East Ninth Street, 29th Floor Cleveland, Ohio 44114 216-696-8700 (Name, Address and Telephone Number |
|
| February 14, 2023 |
EX-99.1 2 d451156dex991.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of the Issuer and further agree that this joint filing agreement be inc |
|
| February 14, 2023 |
ACGN / Aceragen Inc / Castellina Ventures Ltd. - SC 13G/A Passive Investment SC 13G/A 1 d451156dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Aceragen, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00445F109 (CUSIP Number) February 14, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 6, 2023 |
Aceragen ANNOUNCES Recommendation of DaTA monitoring COMMITTEE in TERRA Study Exhibit 99.1 Aceragen ANNOUNCES Recommendation of DaTA monitoring COMMITTEE in TERRA Study DURHAM, N.C. and EXTON, Pa., Feb. 6, 2023 (GLOBE NEWSWIRE) - Aceragen, Inc. (Nasdaq: ACGN) a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the recommendation of its independent Data Monitoring Committee |
|
| February 6, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2023 Aceragen, Inc. |
|
| February 3, 2023 |
Form of Idera Pharmaceuticals, Inc. Convertible Unsecured Promissory Notes Exhibit 4.1 Final Form IDERA PHARMACEUTICALS, INC. CONVERTIBLE UNSECURED PROMISSORY NOTE THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PE |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2023 Aceragen, Inc. |
|
| February 1, 2023 |
As filed with the Securities and Exchange Commission on February 1, 2023 As filed with the Securities and Exchange Commission on February 1, 2023 Registration No. |
|
| February 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Aceragen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Newly Registered Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Proposed Maximum Aggregate Offering Price (2) Fee Rate Am |
|
| January 30, 2023 |
ACGN / Aceragen Inc / Pillar Pharmaceuticals 6, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| January 30, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The under |
|
| January 18, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 18, 2023 Aceragen, Inc. |
|
| January 18, 2023 |
EX-7.03 2 tm233779d1ex7-03.htm EXHIBIT 7.03 Exhibit 7.03 Joint Filing Agreement The undersigned, being duly authorized thereunto, hereby execute this Joint Filing Agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended to file this Schedule 13D, and any su |
|
| January 18, 2023 |
SC 13D 1 tm233779d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Aceragen, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45168K306 (CUSIP Number) Jacob Comer, Partner, General Counsel and Chief Compliance Officer NovaQuest Co-Investment |
|
| January 18, 2023 |
Therapeutics for Rare Pulmonary & Rheumatic Diseases Nasdaq: ACGN January 2023 Exhibit 99.1 Therapeutics for Rare Pulmonary & Rheumatic Diseases Nasdaq: ACGN January 2023 Important Information The information provided in this presentation pertaining to Aceragen , Inc . (“ Aceragen ” or “Company”) is for informational purposes only to assist interested parties in making their own independent evaluation . Information contained in this presentation should not be relied upon as |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2023 Aceragen, Inc. |
|
| January 17, 2023 |
Certificate of Amendment to Restated Certificate of Incorporation Exhibit 3.1 Delaware The First State Page 1 2197526 8100 Authentication: 202505945 SR# 20230152942 Date: 01-17-23 You may verify this certificate online at corp.delaware.gov/authver.shtml I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “IDERA PHARMACEUTICALS, INC.”, CHANGING ITS NAME FR |
|
| January 17, 2023 |
Exhibit 99.1 Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, NC and EXTON, Pa, January 17, 2023 — Idera Pharmaceutical |
|
| January 13, 2023 |
Idera Pharmaceuticals, Inc. 2022 Stock Incentive Plan Exhibit 10.1 IDERA PHARMACEUTICALS, INC. 2022 EQUITY INCENTIVE PLAN Section 1. Effectiveness and Purpose. Effective as of the Effective Date, the Idera Pharmaceuticals, Inc. 2022 Equity Incentive Plan (as may be amended from time to time, the “Plan”) is hereby established. The purpose of the Plan is to provide employees of Idera Pharmaceuticals, Inc., a Delaware corporation (together |
|
| January 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 12, 2023 Idera Pharmaceuticals, Inc. |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2023 Idera Pharmaceuticals, Inc. |
|
| December 22, 2022 |
Amendment to Aceragen, Inc. 2021 Stock Incentive Plan. EXHIBIT 99.2 Amendment to the ACERAGEN, INC. 2021 STOCK INCENTIVE PLAN This Amendment (this “Amendment”) to the Aceragen, Inc. 2021 Stock Incentive Plan (the “Plan”), is effective as the Effective Date (as defined below). W I T N E S S E T H: WHEREAS, Aceragen, Inc. (“Aceragen”) maintains the Plan; WHEREAS, under Section 9(d) of the Plan, the Board of Directors of Aceragen (the “Board”) may amend, |
|
| December 22, 2022 |
As filed with the Securities and Exchange Commission on December 22, 2022 As filed with the Securities and Exchange Commission on December 22, 2022 Registration No. |
|
| December 22, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Idera Pharmaceuticals, Inc. |
|
| December 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 28, 2022 Idera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State of other jurisdiction of incorporation) 001-31918 (Commission F |
|
| December 8, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? |
|
| November 23, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 22, 2022 Idera Pharmaceuticals, Inc. |
|
| November 18, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? |
|
| November 17, 2022 |
EXHIBIT 3.1 IDERA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATIONS, PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Idera Pharmaceuticals, Inc., a Delaware corporation (the ?Corporation?), that the following resolution was duly adopted by the Board of D |
|
| November 17, 2022 |
Second Amended and Restated Bylaws of Idera Pharmaceuticals, Inc. EXHIBIT 3.1 SECOND AMENDED AND RESTATED BY-LAWS OF IDERA PHARMACEUTICALS, INC. As further amended on November 17, 2022 SECOND AMENDED AND RESTATED BY-LAWS TABLE OF CONTENTS Page Article 1 ? Stockholders 1 Section 1.1 Place of Meetings 1 Section 1.2 Annual Meetings 1 Section 1.3 Special Meetings 1 Section 1.4 Notice of Meetings 1 Section 1.5 Voting List 1 Section 1.6 Quorum 2 Section 1.7 Adjournmen |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 17, 2022 Idera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State of other jurisdiction of incorporation) 001-31918 (Commission File |
|
| November 17, 2022 |
Certificate of Designation of Series B Preferred Stock of Idera Pharmaceuticals, Inc. EXHIBIT 3.2 IDERA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATIONS, PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Idera Pharmaceuticals, Inc., a Delaware corporation (the ?Corporation?), that the following resolution was duly adopted by the Board of D |
|
| November 17, 2022 |
8-A12G 1 tm2230625d28a12g.htm 8-A12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Idera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 04-1187261 (State or other jurisdiction of incorporation or organi |
|
| November 14, 2022 |
EXHIBIT 10.11 THERAPEUTIC DEVELOPMENT AWARD AGREEMENT December 13, 2021 ? ? Development Program: Treatment of Cystic Fibrosis Pulmonary Exacerbations with Oral ACG-721 Awardee: Arrevus Inc. Award Number: ARREVUS21W0 Award Amount: $[***] in accordance with the Payment Schedule attached hereto as Exhibit B ? 1.Award. The Cystic Fibrosis Foundation, a Delaware corporation (?CFF?), is issuing this awa |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 14, 2022 Idera Pharmaceuticals, Inc. |
|
| November 14, 2022 |
EXHIBIT 10.7 SIDE LETTER AGREEMENT This Side Letter Agreement (this ?Agreement?) is made and entered into as of September 28, 2022, by and between Idera Pharmaceuticals, Inc., a Delaware corporation (?Parent?), Bell Merger Sub II, LLC, a Delaware limited liability company (?Surviving Entity?) (solely with respect to Section 4 hereof), and NovaQuest Co-Investment Fund XV, L.P (?NovaQuest,? and toge |
|
| November 14, 2022 |
EXHIBIT 10.12 ? Page 1 of 60 ? BASE AGREEMENT BETWEEN ADVANCED TECHNOLOGY INTERNATIONAL (ATI) 315 SIGMA DRIVE SUMMERVILLE, SC 29486 AND ARREVUS, INC. 2443 LYNN RD, SUITE 210 RALEIGH, NC 27612 DUNS: 080059821 MEDICAL CBRN DEFENSE CONSORTIUM (MCDC) BASE AGREEMENT NO.: 2021-479 Authority: MCDC Other Transaction Agreement (OTA) No. W15QKN-16-9-1002 and 10 U.S.C. ? 2371b. ? ? Page 2 of 60 ? This Agreem |
|
| November 14, 2022 |
Exhibit 99.1 Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Closing of Aceragen acquisition positions combined company for success with late-stage rare disease portfolio EXTON, PA & DURHAM, NC, November 14, 2022 ? Idera Pharmaceuticals, Inc. (?Idera,? the ?Company,? ?we,? ?us,? or ?our?) (Nasdaq: IDRA) today reported its consolidated financial and |
|
| November 14, 2022 |
EXHIBIT 10.9 AMENDMENT TO STOCK AND WARRANT PURCHASE AGREEMENT This Amendment to Stock and Warrant Purchase Agreement (the ?Amendment?) is made effective as of October 25, 2021 (the ?Effective Date?), between Aceragen, Inc., a Delaware corporation with a principal place of business at 15 T.W. Alexander Drive, Suite 318, Research Triangle Park, NC 22709 (?Aceragen?), and NovaQuest Co-Investment Fun |
|
| November 14, 2022 |
EXHIBIT 2.2 AGREEMENT AND PLAN OF MERGER THIS AGREEMENT AND PLAN OF MERGER (as may be amended from time to time, this ?Agreement?) is made and entered into as of October 18, 2021, by and among Aceragen, Inc., a Delaware corporation (?Parent?), Aceragen Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (?Merger Sub?), Arrevus, Inc., a Delaware corporation (the ?Compan |
|
| November 14, 2022 |
EXHIBIT 10.14 ACERAGEN, INC. 2021 STOCK INCENTIVE PLAN 1.Purpose The purpose of this 2021 Stock Incentive Plan (the ?Plan?) of Aceragen, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing suc |
|
| November 14, 2022 |
EXHIBIT 10.8 STOCK AND WARRANT PURCHASE AGREEMENT This Stock and Warrant Purchase Agreement (this ?Agreement?) is entered into as of March 24, 2021 (the ?Effective Date?), between Aceragen, Inc., a Delaware corporation with a principal place of business at 15 T.W. Alexander Drive, Suite 418, Research Triangle Park, NC 22709 (?Aceragen?) and NovaQuest Co-Investment Fund XV, L.P., a Delaware limited |
|
| November 14, 2022 |
EXHIBIT 10.13 ? ? ? PROJECT AGREEMENT NO.:01 ? MCDC BASE AGREEMENT NO.:2021-479 ? PROJECT TITLE: MCDC2104-001; Oral Regimen for Melioidosis Treatment and Post- Exposure Prophylaxis ? PARTIES: Advanced Technology International (?MCDC CMF?) and Arrevus, Inc. (?Project Agreement Holder?) ? This Project Agreement is awarded under the authority of MCDC Other Transaction Agreement No. W15QKN-16-9-1002 a |
|
| November 14, 2022 |
First Amendment to Aceragen, Inc. 2021 Stock Incentive Plan Form of Stock Option Agreement EXHIBIT 10.15 FIRST AMENDMENT TO STOCK OPTION AGREEMENT THIS FIRST AMENDMENT TO STOCK OPTION AGREEMENT (this ?Amendment?), is entered into April , 2022 effective as of [July 19, 2021/October 8, 2021] (the ?Effective Date?) by and between Aceragen, Inc., a Delaware corporation (the ?Company?), and the undersigned recipient (the ?Optionee?). RECITALS WHEREAS, the Company has previously issued to the |
|
| November 14, 2022 |
Sales Distribution and PRV Agreement, by and between Aceragen, Inc. and NovaQuest ? EXHIBIT 10.10 SALES DISTRIBUTION AND PRV AGREEMENT This Sales Distribution and PRV Agreement (this ?Agreement?) is entered into as of October 25, 2021 (the ?Effective Date?), between Aceragen, Inc., a Delaware corporation with a principal place of business at 15 T.W. Alexander Drive, Suite 318, Research Triangle Park, NC 22709 (?Aceragen?), and NovaQuest Co-Investment Fund XV, L.P., a Delaware l |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 14, 2022 |
Idera Pharmaceuticals, Inc. 505 Eagleview Blvd., Suite 212 Exton, Pennsylvania 19341 (484) 348-1600 Idera Pharmaceuticals, Inc. 505 Eagleview Blvd., Suite 212 Exton, Pennsylvania 19341 (484) 348-1600 October 14, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Jane Park Re: Idera Pharmaceuticals, Inc. Request to Withdraw Registration Statement on Form S-3 File No. 333-248560 Ladies an |
|
| October 5, 2022 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) Exhibit 99.3 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned a |
|
| October 5, 2022 |
IDRA / Idera Pharmaceuticals Inc / Pillar Pharmaceuticals 6, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| September 30, 2022 |
Exhibit 10.5 Execution Version September 28, 2022 Bryant Lim 124 Avon Road Haverford, PA 19041 Re: Employment Continuation and Retention Bonus Letter Agreement Dear Bryant: As you are aware, Idera Pharmaceuticals, Inc. (the ?Company?) intends to enter into an Agreement and Plan of Merger by and among the Company, Aceragen, Inc. and certain other parties (the ?Merger Agreement?). In addition, follo |
|
| September 30, 2022 |
Exhibit 10.4 Execution Version September 28, 2022 John Kirby 3830 Berry Ave Drexel Hill, PA 19026 Re: Employment Continuation and Retention Bonus Letter Agreement Dear John: As you are aware, Idera Pharmaceuticals, Inc. (the ?Company?) intends to enter into an Agreement and Plan of Merger by and among the Company, Aceragen, Inc. and certain other parties (the ?Merger Agreement?). In addition, foll |
|
| September 30, 2022 |
Exhibit 10.6 Execution Version EXECUTIVE TRANSITION AND SEPARATION AGREEMENT This Executive Transition and Separation Agreement (this ?Agreement?), is entered into as of the date set forth on the signature page below (the ?Execution Date?), by and between Daniel Soland (?you?) and Idera Pharmaceuticals, Inc., a Delaware corporation (together with its wholly owned subsidiaries and affiliates, the ? |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 28, 2022 Idera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State of other jurisdiction of incorporation) 001-31918 (Commission Fil |
|
| September 30, 2022 |
Certificate of Designations of Series X Preferred Stock Exhibit 3.2 Execution Version IDERA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Idera Pharmaceuticals, Inc., a Delaware corporation (the ?Corporation?), that the following resolution was duly adopte |
|
| September 30, 2022 |
Certificate of Designations of Series Z Non-Voting Convertible Preferred Stock Exhibit 3.1 Execution Version IDERA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES Z NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Idera Pharmaceuticals, Inc., a Delaware corporation (the ?Corporation?), that the following res |
|
| September 30, 2022 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among: IDERA PHARMACEUTICALS, INC., a Delaware corporation; BELL MERGER SUB I, INC., a Delaware corporation; BELL MERGER SUB II, LLC, a Delaware limited liability company; and ACERAGEN, INC., a Delaware corporation Dated as of September 28, 2022 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION 3 1.1 The Merger 3 1.2 Effects of |
|
| September 30, 2022 |
Letter Agreement by and among Dan Salain and Aceragen, Inc., dated February 25, 2021. Exhibit 10.3 February 25, 2021 Dan Salain 837 N Barfield Drive Marco Island, FL 34145 Dear Dan: Aceragen, Inc. (the ?Company?) is pleased to offer you this letter agreement (the ?Letter Agreement?) for employment on the following terms: 1. Position. In addition to your continued participation on the Company?s Board of Directors (the ?Board?), your operating role will be as Chief Operating Officer |
|
| September 30, 2022 |
Letter Agreement by and among John Taylor and Aceragen, Inc., dated February 25, 2021. Exhibit 10.2 February 25, 2021 John Taylor 1216 Riggins Mill Road Cary, NC 27519 Dear John: Aceragen, Inc. (the ?Company?) is pleased to offer you this letter agreement (the ?Letter Agreement?) for employment on the following terms: 1. Position. In addition to your continued participation on the Company?s Board of Directors (the ?Board?), your operating role will be as Chief Executive Officer & Pr |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 28, 2022 Idera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State of other jurisdiction of incorporation) 001-31918 (Commission Fil |
|
| September 30, 2022 |
Exhibit 10.1 Execution Version EXECUTIVE TRANSITION AND SEPARATION AGREEMENT This Executive Transition and Separation Agreement (this ?Agreement?), is entered into as of the date set forth on the signature page below (the ?Execution Date?), by and between Vincent Milano (?you?) and Idera Pharmaceuticals, Inc., a Delaware corporation (together with its wholly owned subsidiaries and affiliates, the |
|
| September 28, 2022 |
Exhibit 99.1 Idera Pharmaceuticals Acquires Aceragen Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, PA and DURHAM, NC, September 28, 2022 ? Idera Pharmaceuticals, Inc. (?Idera,? the ?Company,? ?we,? ?us,? or ?our?) (Nasdaq: IDRA) toda |
|
| September 28, 2022 |
Slide presentation dated September 28, 2022. Exhibit 99.2 Idera Pharmaceuticals + Aceragen A Business Combination to Create a Public Rare Disease Pulmonary & Rheumatology Company September 2022 ? 2022 Idera Important Information expectations include, but are not limited to: whether the Company will be able to successfully integrate the Aceragen operations and realize the anticipated benefits of the acquisition of Aceragen ; whether the Compa |
|
| September 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 28, 2022 Idera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State of other jurisdiction of incorporation) 001-31918 (Commission Fil |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| September 28, 2022 |
Exhibit 99.2 Idera Pharmaceuticals + Aceragen A Business Combination to Create a Public Rare Disease Pulmonary & Rheumatology Company September 2022 ? 2022 Idera Important Information expectations include, but are not limited to: whether the Company will be able to successfully integrate the Aceragen operations and realize the anticipated benefits of the acquisition of Aceragen ; whether the Compa |
|
| September 28, 2022 |
Joint Press Release of Idera Pharmaceuticals, Inc. and Aceragen, Inc., dated September 28, 2022 Exhibit 99.1 Idera Pharmaceuticals Acquires Aceragen Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, PA and DURHAM, NC, September 28, 2022 ? Idera Pharmaceuticals, Inc. (?Idera,? the ?Company,? ?we,? ?us,? or ?our?) (Nasdaq: IDRA) toda |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 9, 2022 Idera Pharmaceuticals, Inc. |
|
| August 9, 2022 |
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results Exhibit 99.1 Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results EXTON, PA, August 9, 2022 ? Idera Pharmaceuticals, Inc. (?Idera,? the ?Company,? ?we,? ?us,? or ?our?) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022. Second Quarter Financial Results Our cash position as of June 30, 2022 was $24.5 million. Based on our c |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 6, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Idera Pharmaceuticals, Inc. |
|
| July 6, 2022 |
As filed with the Securities and Exchange Commission on July 6, 2022 As filed with the Securities and Exchange Commission on July 6, 2022 Registration No. |
|
| July 6, 2022 |
As filed with the Securities and Exchange Commission on July 6, 2022 As filed with the Securities and Exchange Commission on July 6, 2022 Registration No. |
|
| July 6, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Idera Pharmaceuticals, Inc. |
|
| July 1, 2022 |
IDRA / Idera Pharmaceuticals Inc / Pillar Pharmaceuticals 6, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| July 1, 2022 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned a |
|
| June 24, 2022 |
Amendment to 2017 Employee Stock Purchase Plan, as amended EXHIBIT 10.2 AMENDMENT TO THE IDERA PHARMACEUTICALS, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN WHEREAS, Idera Pharmaceuticals, Inc. (the ?Company?) desires to amend the Idera Pharmaceuticals, Inc. 2017 Employee Stock Purchase Plan (the ?ESPP?), in the manner set forth below (the ?Amendment?); and WHEREAS, on April 15, 2022, subject to stockholder approval, the Board of Directors of the Company approv |
|
| June 24, 2022 |
Exhibit 99.2 Idera Pharmaceuticals, Inc. 505 Eagleview Blvd., Suite 212 Exton, Pennsylvania 19341 June 9, 2022 Dear Ladies and Gentlemen, Pillar Invest Corporation, together with its affiliates (?Pillar?, ?we? or ?us?), is pleased to submit this non-binding indication of interest (the ?Proposal?) to acquire Tilsotolimod and all related assets (the ?TLR Platform?) from Idera Pharmaceuticals, Inc. ( |
|
| June 24, 2022 |
IDRA / Idera Pharmaceuticals Inc / Pillar Pharmaceuticals 6, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 23, 2022 Idera Pharmaceuticals, Inc. |
|
| June 24, 2022 |
Amendment to 2013 Stock Incentive Plan, as amended EXHIBIT 10.1 AMENDMENT TO THE IDERA PHARMACEUTICALS, INC. 2013 STOCK INCENTIVE PLAN WHEREAS, Idera Pharmaceuticals, Inc. (the ?Company?) desires to amend the Idera Pharmaceuticals, Inc. 2013 Stock Incentive Plan, as amended (the ?2013 Plan?), in the manner set forth below (the ?Amendment?); and WHEREAS, on April 15, 2022, subject to stockholder approval, the Board of Directors of the Company appro |
|
| June 24, 2022 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned a |
|
| June 7, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule |
|
| June 7, 2022 |
IDRA / Idera Pharmaceuticals Inc / Castellina Ventures Ltd. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* IDERA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities) 45168K306 (CUSIP Number) May 18, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 26, 2022 Idera Pharmaceuticals, Inc. |
|
| May 17, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 17, 2022 Idera Pharmaceuticals, Inc. |
|
| May 17, 2022 |
Exhibit 99.1 Idera Pharmaceuticals Shares Positive Results from Investigator- Sponsored Trial in Melanoma Patients at Amsterdam UMC – Enrollment Stopped Early for Efficacy – EXTON, PA, May 17, 2022— Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 5, 2022 |
Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update EXTON, PA, May 5, 2022 — Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2022. “We continue to preserve cash while actively pursuing new development or comme |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 5, 2022 Idera Pharmaceuticals, Inc. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 29, 2022 |
Proposal 5 – Approval of Amendment to 2017 Employee Stock Purchase Plan TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.????????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted b |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 31, 2022 Idera Pharmaceuticals, Inc. |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K ? ?ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the Fiscal Year Ended December 31, 2021 ? or ? ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Commission File Number: 001-31918 ? ? IDERA PHARMACEUTICALS, INC. |
|
| March 31, 2022 |
EX-99.1 2 tm2211072d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update EXTON, PA, March 31, 2022 — Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2021. “W |
|
| March 31, 2022 |
Idera Pharmaceuticals, Inc. Up to $10,431,194 Common Stock PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2020) Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| February 8, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule |
|
| February 8, 2022 |
IDRA / Idera Pharmaceuticals Inc / Castellina Ventures Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* IDERA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities) 45168K306 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| December 14, 2021 |
Idera Pharmaceuticals Announces Tilsotolimod Updates Exhibit 99.1 Idera Pharmaceuticals Announces Tilsotolimod Updates EXTON, PA, December 14, 2021 ? Idera Pharmaceuticals, Inc. (?Idera,? the ?Company,? ?we,? ?us,? and ?our?) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist. ILLUMINATE-206 Trial for the Treatment of Previously Treated Patients with Immunotherapy-Na?ve Micro-Satellite |
|
| December 14, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 14, 2021 Idera Pharmaceuticals, Inc. |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 26, 2021 Idera Pharmaceuticals, Inc. |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 8, 2021 Idera Pharmaceuticals, Inc. |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 8, 2021 |
Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update EXTON, PA, November 8, 2021 ? Idera Pharmaceuticals, Inc. (?Idera,? the ?Company,? ?we,? ?us,? or ?our?) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2021. ?We are maintaining our focus on identifying new development or comme |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 9, 2021 Idera Pharmaceuticals, Inc. |
|
| August 9, 2021 |
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update EXTON, PA, August 9, 2021 ? Idera Pharmaceuticals, Inc. (?Idera? or the ?Company?) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021. ?Our goal is to add new development or commercial-stage assets to Idera?s portfolio, and our t |
|
| June 10, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 8, 2021 Idera Pharmaceuticals, Inc. |
|
| June 7, 2021 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned a |
|
| June 7, 2021 |
IDRA / Idera Pharmaceuticals Inc / Pillar Pharmaceuticals 6, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| May 24, 2021 |
Idera Pharmaceuticals, Inc. 505 Eagleview Blvd., Suite 212 Exton, Pennsylvania 19341 Idera Pharmaceuticals, Inc. 505 Eagleview Blvd., Suite 212 Exton, Pennsylvania 19341 May 24, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention:???????Abby Adams Re:???????????Idera Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 3, 2021 File No. 333-253804 Ladies and Gentlemen: Pursuant to Rule |
|
| May 19, 2021 |
As filed with the Securities and Exchange Commission on May 18, 2021 As filed with the Securities and Exchange Commission on May 18, 2021 Registration No. |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 18, 2021 Idera Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-31918 (Commission File Number) |
|
| May 18, 2021 |
Idera Pharmaceuticals Announces Corporate Updates Exhibit 99.1 Idera Pharmaceuticals Announces Corporate Updates EXTON, PA, May 18, 2021 ? Idera Pharmaceuticals, Inc. (?Idera? or the ?Company?) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company?s trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, to its overall survival (OS) primar |
|
| May 18, 2021 |
Consulting Agreement, dated May 18, 2021, between the Company and Elizabeth Tarka, M.D. Exhibit 10.1 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDMENT TO SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS AMENDMENT TO CHANGE OF CONTROL AGREEMENT between Elizabeth A. Tarka, M.D. (the "Executive") and Idera Pharmaceuticals, Inc. (''the Company'') shall be effective May 28, 2021 (the ?Date of Termina |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 29, 2021 Idera Pharmaceuticals, Inc. |
|
| April 29, 2021 |
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update EXTON, PA, April 29, 2021 ? Idera Pharmaceuticals, Inc. (?Idera? or the ?Company?) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2021. ?Despite the disappointing objective response rate (ORR) results from ILLUMINATE-301, our Phase |
|
| April 29, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2021 |
our definitive proxy statement on Schedule 14A for the 2021 Annual Meeting of the Stockholders. TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???????? ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitte |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 9, 2021 |
SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 1, 2021 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| April 1, 2021 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The under |
|
| March 18, 2021 |
Exhibit 99.1 Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma ? Objective Response Rate Endpoint Not Met ? EXTON, PA, March 18, 2021 ? Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the ?Company?) today is announcing that ILLUMINATE-301, the Company?s pivotal registration trial of tilsotolimod in combination with i |
|
| March 18, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 18, 2021 Idera Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-31918 (Commission File Number |
|
| March 3, 2021 |
Power of Attorney (included on the signature page of this registration statement) As filed with the Securities and Exchange Commission on March 2, 2021 Registration No. |
|
| March 1, 2021 |
? Exhibit 10.25 ? ? ? ? November 16, 2020 ? Daniel Soland [Street Address] [City, State, Zip Code] Dear Daniel, ? On behalf of Idera Pharmaceuticals, Inc., ("Company"), we are pleased to offer you the position of Senior Vice President & Chief Operating Officer, reporting directly to Vin Milano, President & CEO. This role will report to our Exton Pennsylvania office. Your start date will be determi |
|
| March 1, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K ? ?ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the Fiscal Year Ended December 31, 2020 ? or ? ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Commission File Number: 001-31918 ? ? IDERA PHARMACEUTICALS, INC. |
|
| March 1, 2021 |
Exhibit 10.26 ? SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between Idera Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and Daniel Soland (the "Executive"), dated as of February 19, 2021. ? WHEREAS, the Board of Directors of the Company (the "Board"), has determined that it is in the best interests of the Company and its shareholders to assure that |
|
| March 1, 2021 |
Exhibit 4.21 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? The following description sets forth certain material terms and provisions of Idera Pharmaceuticals, Inc.?s (?Idera,? ?we,? ?us,? and ?our?) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. ? The following description |
|
| March 1, 2021 |
Exhibit 99.1 Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update ILLUMINATE-301 Continues on Track for Data Later this Month EXTON, PA, March 1, 2021 — Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020. “Tilsoto |
|
| March 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 1, 2021 Idera Pharmaceuticals, Inc. |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* IDERA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities) 45168K306 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 12, 2021 |
EX-99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this |
|
| January 29, 2021 |
SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 13, 2021 Idera Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-31918 (Commission File Numbe |
|
| January 13, 2021 |
Exhibit 99.1 Our Time is Now January 2021 Forward - Looking Statements & Other Important Cautions This presentation contains forward - looking statements within the meaning of safe harbor of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws including statements about Idera Pharmaceuticals, Inc.’s (the “Company” or “ Idera ”) expectations for, and obligations unde |
|
| January 11, 2021 |
Idera Pharmaceuticals to Present at Upcoming Conferences Exhibit 99.1 Idera Pharmaceuticals to Present at Upcoming Conferences EXTON, PA, January 11, 2021 — Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. “2021 represents a pivotal inflection point for Idera, one in which we anticipate that data soon to be available from our ILLUMINATE program will show that tilsotolimod |
|
| January 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 11, 2021 Idera Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-31918 (Commission File Numb |
|
| January 5, 2021 |
Consulting Agreement, dated December 29, 2020, between the Company and R. Clayton Fletcher Exhibit 10.1 CONSULTING SERVICES AGREEMENT THIS CONSULTING SERVICES AGREEMENT (the “Agreement”) is made and entered into on December 29, 2020 (the “Effective Date”) by and between Idera Pharmaceuticals, Inc., having a place of business at 505 Eagleview Boulevard, Suite 212, Exton, Pennsylvania 19341, USA (hereinafter referred to as “Idera”) and Hilltop Consulting, LLC, having a place of business l |
|
| January 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 5, 2021 (December 29, 2020) Idera Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-31918 (C |
|
| December 30, 2020 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| December 15, 2020 |
Exhibit 10.2 Idera Pharmaceuticals, Inc. AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT This Amendment to the Prior SPA and the Prior RRA (each as defined below) effective as of December 11, 2020, is made by and between Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Pillar Partners Foundation, L.P., a Cayman Islands limited partnership (“Pill |
|
| December 15, 2020 |
Exhibit 99.1 Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million EXTON, PA, December 15, 2020 — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Purchase Agreement”), resulting in aggregate proceeds of up to $20.7 million in common stock |
|
| December 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 11, 2020 Idera Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-31918 (Commission File Num |
|
| November 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 17, 2020 Idera Pharmaceuticals, Inc. |
|
| November 17, 2020 |
Exhibit 99.1 Idera Pharmaceuticals Contacts: Jill Conwell Investor Relations & Corporate Communications Phone (484) 348-1675 [email protected] John J. Kirby Chief Financial Officer Phone (484) 348-1627 [email protected] Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer ? COO Role is Key to Preparedness for NDA Filing and Commercial Launch ? ? Clayton Fletche |
|
| October 29, 2020 |
Idera Pharmaceuticals Contacts: Jill Conwell Investor Relations & Corporate Communications Phone (484) 348-1675 JConwell@IderaPharma. |
|
| October 29, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to . Commission File Number: 001-31918 |
|
| October 29, 2020 |
Form of Performance-Based Restricted Stock Agreement under the 2013 Stock Incentive Plan Exhibit 10.3 IDERA PHARMACEUTICALS, INC. 2013 STOCK INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT This PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT (the “Agreement”), dated as of (the “Date of Grant”), is delivered by Idera Pharmaceuticals, Inc. (the “Company”) to (the “Participant”). RECITALS The Idera Pharmaceuticals, Inc. 2013 Stock Incentive Plan (the “Plan”) provides f |
|
| October 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 29, 2020 Idera Pharmaceuticals, Inc. |
|
| September 28, 2020 |
Exhibit 99.1 IDERA PHARMACEUTICALS CONTACTS: Jill Conwell Investor Relations & Corporate Communications Phone (484) 348-1675 [email protected] John J. Kirby Chief Financial Officer Phone (484) 348-1627 [email protected] Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037 – Protects Method-of-Use in CRC and HNSCC– EXTON, PA, September 28, 202 |
|
| September 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 28, 2020 Idera Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-31918 (Commission File Nu |
|
| September 3, 2020 |
Idera Pharmaceuticals, Inc. Up to $30,173,865 Common Stock PROSPECTUS SUPPLEMENT (To Prospectus dated August 4, 2020) Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| September 3, 2020 |
Exhibit 10.1 FIRST AMENDMENT TO PURCHASE AGREEMENT THIS FIRST AMENDMENT TO PURCHASE AGREEMENT (this “First Amendment”), dated as of September 2, 2020, by and between IDERA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS, the Company and the Investor entered into that certain Purchase |
|
| September 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2020 (September 2, 2020) Idera Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-31918 |
|
| September 2, 2020 |
As filed with the Securities and Exchange Commission on September 2, 2020 Registration No. |
|
| September 2, 2020 |
PROSPECTUS SUPPLEMENT (To Prospectus dated August 4, 2020) Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| August 31, 2020 |
Idera Pharmaceuticals, Inc. 505 Eagleview Blvd., Suite 212 Exton, Pennsylvania 19341 August 31, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Idera Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 4, 2020 File No. 333-240366 Ladies and Gentlemen: Pursuant to Rule 461 unde |
|
| August 17, 2020 |
IDRA / Idera Pharmaceuticals, Inc. / Pillar Pharmaceuticals I LP - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| August 12, 2020 |
Idera Pharmaceuticals, Inc. 505 Eagleview Blvd., Suite 212 Exton, Pennsylvania 19341 August 12, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Idera Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 4, 2020 File No. 333-240361 Ladies and Gentlemen: Pursuant to Rule 461 unde |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 4, 2020 Idera Pharmaceuticals, Inc. |
|
| August 4, 2020 |
As filed with the Securities and Exchange Commission on August 4, 2020 Registration No. |
|
| August 4, 2020 |
Exhibit 99.1 IDERA PHARMACEUTICALS Contacts: Jill Conwell Investor Relations & Corporate Communications Phone (484) 348-1675 [email protected] John J. Kirby Chief Financial Officer Phone (484) 348-1627 [email protected] Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update Enhanced Financial Flexibility as ILLUMINATE-301 Continues on Track EXTON, |
|
| August 4, 2020 |
As filed with the Securities and Exchange Commission on August 4, 2020 Registration No. |
|
| August 4, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to . Commission File Number: 001-31918 IDERA |
|
| July 15, 2020 |
Form of Warrant issuable pursuant to the July 2020 Securities Purchase Agreement Exhibit 4.2 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIE |
|
| July 15, 2020 |
Form of Pre-Funded Warrant issuable pursuant to the July 2020 Securities Purchase Agreement Exhibit 4.1 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIE |
|
| July 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 13, 2020 Idera Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-31918 (Commission File Number) |
|
| July 15, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made and entered into as of July 13, 2020 (the “Effective Date”) by and among Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and entities controlled by Pillar Invest Corporation, Cayman Islands limited partnerships, set forth on Schedule A hereto (each a “Purchaser” and togethe |
|
| July 15, 2020 |
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million Exhibit 99.1 Idera Pharmaceuticals Contacts: Jill Conwell Investor Relations & Corporate Communications Phone (484) 348-1675 [email protected] John J. Kirby Chief Financial Officer Phone (484) 348-1627 [email protected] Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million EXTON, PA, July 15, 2020 — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering |
|
| July 15, 2020 |
Exhibit 4.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of July 13, 2020, by and between Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and entities controlled by Pillar Invest Corporation, Cayman Islands limited partnerships, set forth on Schedule A hereto (each an “Investor” and together the “Investors”). Unless otherwise de |
|
| June 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 9, 2020 Idera Pharmaceuticals, Inc. |
|
| June 10, 2020 |
Idera Pharmaceuticals, Inc. 505 Eagleview Blvd., Suite 212 Exton, Pennsylvania 19341 June 10, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada Sarmento Re: Idera Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 2, 2020 File No. 333-238868 Ladies and Gentlemen: Pursuant to Rule 461 under the |
|
| June 2, 2020 |
Exhibit 99.1 Idera Pharmaceuticals Contacts: Jill Conwell Investor Relations & Corporate Communications Phone (484) 348-1675 [email protected] John J. Kirby Chief Financial Officer Phone (484) 348-1627 [email protected] Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer |
|
| June 2, 2020 |
As filed with the Securities and Exchange Commission on June 2, 2020 Registration No. |
